pfizer glp-1 agonist Is Going All In on Drugs Through China 2 Companies Poised to Capitalize
Description
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
Capsules may be opened, and contents may be added to water or juice
The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity
Thats how unsafe and unregulated products gain ground
A new deal may cut the cost of weight-loss drugs, but this UVA professor warns of potential long-term risks.
